Market Place
Sourcing Support
Merck Doses First Patient In Phase III Cladribine Study For gMG
30 Aug 2024 //
BUSINESSWIRE
BioNxt Signs Statement For Cladribine ODF Development With CRO
17 Jul 2024 //
ACCESSWIRE
BioNxt Solutions Announces ODF Cladribine Update and Financing
25 Apr 2024 //
ACCESSWIRE
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
18 Mar 2024 //
ACCESSWIRE
Merck Presents New MAVENCLAD® (Cladribine Tablets) Data
10 Oct 2023 //
BUSINESSWIRE
EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data
10 Oct 2023 //
BUSINESSWIRE
Obesity drugs don`t make WHO`s essential list, but Ebola, MS drugs added
27 Jul 2023 //
REUTERS
Enforcement Report - Week of January 4, 2023
04 Jan 2023 //
FDA
FDA Confirms Paragraph IV Patent Litigation for Cladribine
13 Jun 2022 //
FDA
New MAVENCLAD Data at ACTRIMS Forum 2022 Show Favourable Efficacy Outcomes
24 Feb 2022 //
BUSINESSWIRE
Merck KGaA snatches up Geneva biotech as chemotherapy mission strikes a `Chord`
20 Dec 2021 //
ENDPTS
Actinium Shows 72% MRD Negativity Rate in Phase 1 Study of Actimab-A + CLAG-M
14 Dec 2021 //
PRNEWSWIRE
New MAVENCLAD Data Show Sustained Effectiveness and Benefit in RMS Patients
13 Oct 2021 //
BUSINESSWIRE
EMD Serono Completes Enrollment of Evobrutinib Phase III Clinical Trials
04 Oct 2021 //
BUSINESSWIRE
EMD Serono Completes Enrollment of Evobrutinib Phase III Clinical Trials
04 Oct 2021 //
BUSINESSWIRE
MAVENCLAD (cladribine tablets) is available through public drug plans
27 Oct 2020 //
BIOSPACE
EMD Serono to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020
03 Sep 2020 //
PRNEWSWIRE
Prime and EMD Serono ink value-based agreement on MAVENCLAD®
08 Jun 2020 //
PRNEWSWIRE
Merck KGaA`s Mavenclad stakes its claim in competitive MS market
05 Mar 2020 //
FIERCE PHARMA
Mavenclad granted accelerated access by NICE
25 Nov 2019 //
PHARMATIMES
Merck KGaA`s MS launch Mavenclad offsets Rebif sales shortfall
14 Nov 2019 //
FIERCE PHARMA
Merck KGaA touts Mavenclad data as MS new drug race heats up
14 Sep 2019 //
FIERCE PHARMA
Merck announces RWD support long-term efficacy and safety profile of Mavenclad
13 Sep 2019 //
PHARMABIZ
Merck KGaA touts FDA `breakthrough` status
12 Sep 2019 //
ENDPOINTS NEWS
AllianceRx Walgreens Prime Issues Updated List of New Specialty Drugs
16 Aug 2019 //
PR NEWSWIRE
Novartis Gilenya staves off geric challengers? - for now.
26 Jun 2019 //
FIERCE PHARMA
Merck KGaA receives approval for oral dose MS treatment
10 Apr 2019 //
IN-PHARMATECHNOLOGIST
Merck KGaA finally chalks up FDA nod for MS med Mavenclad
02 Apr 2019 //
FIERCE PHARMA
FDA Approves MAVENCLAD® Tablets as First and Only Short-Course Oral Treatment
29 Mar 2019 //
PR NEWSWIRE
Merck announces innovative MS treatment MAVENCLAD® (Cladribine Tablets)
23 Nov 2018 //
BIOSPACE
Up to 10-Years of Follow-up Data Reaffirm Safety Profile of Cladribine Tablets
10 Oct 2018 //
PR NEWSWIRE
FDA Accepts Cladribine Tablets as Potential Treatment for r/r MS
30 Jul 2018 //
PR NEWSWIRE
Merck`s MS treatment shows promise in new data
02 May 2018 //
PHARMA TIMES
AstraZeneca leukemia drug bags priority review status
04 Apr 2018 //
FIERCE BIOTECH
UPDATE 1-Chinese competition weighs on Merck KGaA`s 2018 outlook
07 Mar 2018 //
REUTERS
Medicare Rigid Billing System Leaves Gilead Cancer Drug in Limbo
15 Dec 2017 //
BLOOMBERG
Germany`s Merck to make new bid to enter U.S. MS pill market
15 Dec 2017 //
REUTERS
New analysis backs benefit-risk profile of Merck’s Mavenclad
27 Oct 2017 //
PHARMA TIMES
Merck’s MS pill Mavenclad launched in the UK and Ireland
21 Sep 2017 //
PHARMA TIMES
Merck Serono Europe`s Mavenclad cladribine Receives Approval In Europe
09 Sep 2017 //
EMA
After a long, painful revamp, Merck KGaA scores key OK defunct cladribine
26 Aug 2017 //
ENDPTS
EU nod for Merck’s MS therapy Mavenclad
26 Aug 2017 //
PHARMA TIMES
Data revealed under FOI shows benefit of MS drug currently blocked by regulators
17 Aug 2017 //
EUREKA ALERT
Merck`s pharma unit faces tougher 2017 as fertility boost recedes
17 Nov 2016 //
PMLIVE
Zhejiang Hisun Pharmaceutical, Co., Ltd. (Yantou Campus) Fails EDQM Inspection
19 Sep 2016 //
EDQM
Pharma R&D underachiever Merck KGaA gambles €250M on a PhIII comeback
11 Dec 2015 //
FIERCE BIOTECH
Merck KGaA reworks healthcare exec team with new COO, CMO
15 Sep 2015 //
FIERCE PHARMA
Merck KGaA tries to revive multiple sclerosis pill cladribine
11 Sep 2015 //
REUTERS
